Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the canary prostate active surveillance study

Clinical Cancer Research

Volumn 19, Issue 9, 2013, Pages 2442-2450

  Lin, Daniel W ^a,b   Newcomb, Lisa F ^a,b   Brown, Elissa C ^a   Brooks, James D ^c   Carroll, Peter R ^d   Feng, Ziding ^a   Gleave, Martin E ^e   Lance, Raymond S ^f   Sanda, Martin G ^g   Thompson, Ian M ^h   Wei, John T ⁱ   Nelson, Peter S ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h Mays Cancer Center at UT Health San Antonio   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TMPRSS2 ERG FUSION PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; TUMOR VOLUME; URINALYSIS; URINE LEVEL;

EID: 84877097685     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3283     Document Type: Article

References (44)

1. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117-23.
2. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101. (Pubitemid 40617061)
3. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9. (Pubitemid 38725420)
4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13.
5. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141-9. (Pubitemid 41095147)
6. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:S14-S9.
7. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134-41. (Pubitemid 44288788)
8. Moyer VAon behalf of the USPSTF. Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012;157:120-34.
9. Andriole GL, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
10. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
11. Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 1994;152:1709-13. (Pubitemid 24322612)
12. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359-65. (Pubitemid 350052183)
13. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the johns hopkins experience. J Clin Oncol 2011;29:2185-90.
14. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
15. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664-70. (Pubitemid 351969209)
16. Dall'era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-83.
17. Peyromaure M, Ravery V, Messas A, Toublanc M, Boccon-Gibod L, Boccon-Gibod L. Pain and morbidity of an extensive prostate 10-biopsy protocol: a prospective study in 289 patients. J Urol 2002;167:218-21. (Pubitemid 34024536)
18. Naughton CK, Ornstein DK, Smith DS, Catalona WJ. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol 2000;163:168-71.
19. Bussemakers MJG, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HFM, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9. (Pubitemid 30004960)
20. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
21. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
22. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95. (Pubitemid 43794421)
23. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008;180:1975-8.
24. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804-9.
25. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011;59:422-9.
26. van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, et al. The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance. BJU Int 2012;109:360-6.
27. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
28. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009;56:275-86.
29. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9. (Pubitemid 47037039)
30. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication of the fusion of TMPRSS2 to ERG sequence identifies fatal human prostate cancer. Oncogene 2008;27:253-63.
31. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2:ERG fusion transcript stratifi es prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011;3:94ra72.
32. Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, et al. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology 2010;75:407-13.
33. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-42. (Pubitemid 41232997)
34. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
35. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 2003;169:2136-41. (Pubitemid 36576734)
36. Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol 2004;171:1093-7. (Pubitemid 38327534)
37. Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC, Epstein JI. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J Urol 2005;173:450-3.
38. Klatte T, Waldert M, de Martino M, Schatzl G, Mannhalter C, Remzi M. Age-specific PCA3 score reference values for diagnosis of prostate cancer. World J Urol 2012;30:405-10.
39. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011;29:228-34.
40. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012;156:591-5.
41. Stav K, Judith S, Merald H, Leibovici D, Lindner A, Zisman A. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer? Urol Oncol 2007;25:383-6. (Pubitemid 47362756)
42. Iremashvili V, Pelaez L, Jorda M, Manoharan M, Arianayagam M, Rosenberg DL, et al. Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in prostatectomy specimens. Urology 2012;79:37-42.
43. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010;183:534-8.
44. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, et al. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol 2011;186:465-9.